Phillip Schneider Buys Shares of ARS Pharmaceuticals
Phillip Schneider recently acquired 30,000 shares of ARS Pharmaceuticals, Inc.
Key Points
- Phillip Schneider purchased 30,000 shares of ARS Pharmaceuticals on June 24, 2026.
- Shares of ARS Pharmaceuticals traded at $8.54 on Saturday, with a market cap of $848 million.
- Analysts maintain a strong buy consensus with a mean price target of $28.4.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Phillip Schneider made a move in the stock market by purchasing 30,000 shares of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) on June 24, 2026. This insider transaction wasn't part of a pre-planned program, indicating a direct investment choice by Schneider.
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
Several insiders at ARS Pharmaceuticals have been active in the market. On June 24, along with Phillip Schneider, insiders like Peter Thompson, Laura Shawver, and Rajeev Dadoo each bought 30,000 shares. These transactions, like Schneider's, were not under any pre-planned trading programs.
ARS Pharmaceuticals, Inc. Stock Up 45.0%
On Saturday, ARS Pharmaceuticals' shares were trading at $8.54. The company has a market cap of approximately $848 million. With a forward P/E ratio currently not meaningful due to lack of profitability, the biotech firm has a beta of 0.826, suggesting lower volatility compared to the market. Over the past year, the stock has seen a low of $6.66 and a high of $18.90, with a current 50-day moving average of $8.70 and a 200-day moving average of $9.36.
$SPRY stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analyst firms remain optimistic about ARS Pharmaceuticals. On June 25, 2026, Leerink Partners maintained its buy rating with a price target of $24. Cantor Fitzgerald also maintained a buy rating, setting a target of $30 in their May 28, 2026 report. Overall, the stock has a strong buy consensus with an average target price of $28.4, based on five analyst opinions.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biotech company based in San Diego, California. Founded in 2015, the company focuses on developing treatments for severe allergic reactions. Its main product, Neffy, is an intranasal delivery system for epinephrine, offering a needle-free solution for emergency treatment of Type I allergic reactions, including anaphylaxis. The company employs 154 people and is led by CEO Richard E. Lowenthal.
Bottom Line
Phillip Schneider's recent purchase of ARS Pharmaceuticals shares is part of a broader trend of insider buying at the company. With shares trading at $8.54 and a market cap of $848 million, ARS Pharmaceuticals continues to attract attention from both insiders and analysts. Investors will be watching closely as the company progresses with its innovative treatments. Remember, insider transactions like these are reported after the fact and don't necessarily indicate future performance.
Get ARS Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.